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Abstract
Cytology-based screening for invasive cervical cancer (ICC) lacks sensitivity and specificity to discriminate between cervical
intraepithelial neoplasia (CIN) likely to persist or progress from cases likely to resolve. Genome-wide approaches have been
used to identify DNA methylation marks associated with CIN persistence or progression. However, associations between
DNA methylation marks and CIN or ICC remain weak and inconsistent. Between 2008–2009, we conducted a hospital-based,
case-control study among 213 Tanzania women with CIN 1/2/3 or ICC. We collected questionnaire data, biopsies, peripheral
blood, cervical scrapes, Human papillomavirus (HPV) and HIV-1 infection status. We assessed PEG3 methylation status by
bisulfite pyrosequencing. Multinomial logistic regression was used to estimate odds ratios (OR) and confidence intervals (CI
95%) for associations between PEG3 methylation status and CIN or ICC. After adjusting for age, gravidity, hormonal
contraceptive use and HPV infection, a 5% increase in PEG3 DNA methylation was associated with increased risk for ICC
(OR = 1.6; 95% CI 1.2–2.1). HPV infection was associated with a higher risk of CIN1-3 (OR = 15.7; 95% CI 5.7–48.6) and ICC
(OR = 29.5, 95% CI 6.3–38.4). Infection with high risk HPV was correlated with mean PEG3 differentially methylated regions
(DMRs) methylation (r = 0.34 p,0.0001), while the correlation with low risk HPV infection was weaker (r = 0.16 p = 0.047).
Although small sample size limits inference, these data support that PEG3 methylation status has potential as a molecular
target for inclusion in CIN screening to improve prediction of progression.Impact statement: We present the first evidence
that aberrant methylation of the PEG3 DMR is an important co-factor in the development of Invasive cervical carcinoma
(ICC), especially among women infected with high risk HPV. Our results show that a five percent increase in DNA
methylation of PEG3 is associated with a 1.6-fold increase ICC risk. Suggesting PEG3 methylation status may be useful as a
molecular marker for CIN screening to improve prediction of cases likely to progress.
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Introduction
Approximately half a million women throughout the world are
diagnosed with cervical cancer annually and slightly over half of
these women die from the disease; 80% are diagnosed in resource-
poor settings [1]. Cytology-based screening and aggressive
treatment of pre-cancerous lesions are the most widely used
strategies for preventing invasive cervical cancer (ICC) worldwide.
Human papillomavirus (HPV), the only known etiologic agent for
ICC, has been used to further stratify CIN cases from women with
normal cytology, with high sensitivity [2] but low specificity.
Overall, approximately 4–10% of women with normal cytology
are HPV DNA positive, and thus the sensitivity and specificity for
HPV DNA testing remains suboptimal, resulting in a non-
negligible number of women with false positive results, requiring
follow-up at cost to both the health care system and the patient.
Suboptimal sensitivity and specificity also has been shown to
decrease adherence to recommended follow-up visits [3]. The use
of cofactors previously associated with CIN or ICC such as age,
parity, cigarette smoking, Chlamydia trachomatis infection, and
long-term hormonal contraceptive use has not yielded additional
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insights for discriminating among CIN1 cases likely to persist or
progress from those likely to regress. Thus, identifying specific
molecular features that can improve prediction of which CIN
cases are likely to progress to ICC remains a priority.
Epigenetic mechanisms of gene regulation, including DNA
methylation, have an important role in coordinating gene
expression changes in response to viral infection [4]. Epigenetic
changes are also proposed as a driving force in the carcinogenic
process that may be involved in the trajectory of HPV infections
progressing from CIN to ICC [5] [6,7]. However, the identity of
such a specific epigenetic target(s) is still unknown. PEG3 is a
paternally expressed imprinted gene on chromosome 19q13.43
that encodes a protein with tumor suppressive function that plays a
role in facilitating p53/c-myc-mediated apoptosis. PEG3 is regu-
lated by allele-specific DNA methylation whereby only the
maternally derived allele is normally methylated. Hypermethyla-
tion at the PEG3 regulatory differentially methylated region
(DMR) leads to a decrease in PEG3 transcription, which in turn is
presumed to inhibit the pro-apoptotic function of this gene [8,9].
Aberrant methylation at this DMR has been associated with lower
levels of PEG3 expression of this tumor suppressor as has been
observed in other gynecologic cancers, including such as ovarian
and endometrial cancers [10] [11] [12]. In addition, PEG3 DMR
hypermethylation and transcriptional silencing has also been
shown to occur in gliomas [13] [14]. These results together suggest
that the PEG3 zinc finger protein may function as a tumor
suppressor gene in cancer, and may be particularly relevant to
cancers affecting the female reproductive tract. We therefore
sought to determine if and how methylation changes at the




Between November 2008 and March 2009, eligible study
participants were recruited from the Reproductive Health Clinic
(RHC) at KCMC, a Cervical Cancer prevention clinic funded by
the World Health Organization. Methods for participant identi-
fication and enrollment have been previously described [15].
Briefly, inclusion criteria were women aged 18 years or older with
no prior history of an abnormal Pap test. Some of the participants
were patients with suspicious ICC lesions referred to KCMC for
an open and colposcopic directed biopsy. Of the 250 women
enrolled, two refused to participate resulting in a 99% response
rate. Of the remaining 248 there were 14 where we were unable to
determine cancer diagnoses and 21 without HPV results. The final
study population comprised 213 women with questionnaire, CIN/
ICC, HIV-1 status, and HPV genotype data. Thus, cases were
women with any grade of CIN1/2/3 or ICC, and controls were
women without CIN or ICC as assessed during a cytology-based
screening visit.
Ethics Statement
Written informed consent was obtained from each study
participant prior to enrollment. Research Ethics Boards at
Kilimanjaro Christian Medical Centre (KCMC), the University
North Carolina at Chapel Hill and Duke University approved this
study.
Data Collection
Questionnaires. A trained nurse-interviewer obtained in-
formed consent and administered a standardized in-person 40-
minute questionnaire. Socio-demographic characteristics collected
included age, martial status, type of marriage (polygamy vs.
monogamy), tribe, educational attainment, cigarette smoking,
alcohol consumption, reproductive history (e.g. menarche, parity
and gravidity), sexual history (e.g. lifetime number of sexual
partners, age at first intercourse), and medication and supplement
use.
Specimens. Two cervical scrapes were obtained from each
participant. One was prepared on a glass slide for cytological
evaluation for CIN and ICC diagnosis, data also used as outcome
for this study. The second specimen was collected using a
cytobrush and rinsed into Preserv-Cyt TM media (Hologic, Inc
Malborough, MA). One-third of the specimen was reserved for
HPV analysis and stored at 4uC, and the remaining two-thirds
were centrifuged to pellet the cells, which were stored as aliquots at
280uC. DNA extracted from these cells was later used for DNA
methylation analysis. Biopsy specimens were collected only when
clinically indicated. Routine cervical screening by visual inspection
with acetic acid (VIA) was performed. If there were positive
findings by VIA or through direct examination, the patient was
triaged and treated accordingly. Patients with negative findings
were given follow up appointments within two weeks to provide
results.
Ascertainment of the study outcomes: CIN and
carcinoma. The pathologist at KCMC (BS) processed and
read the Papanicolaou smears and biopsy specimens using
standard conventions according to ASCCP guidelines as appro-
priate (http://www.asccp.org/). A gynecologist (BV) also reviewed
medical charts monthly for HIV-1 test and cyto-pathological
results to classify the cases using the Bethesda classification system.
The results were then coded based on pathology and medical
record findings. They were coded as 1) no evidence of cytological
abnormality, 2) mild dysplasia including LSIL and CIN1, 3)
moderate dysplasia including HSIL and CIN2-3, or 4) cancer that
was primarily squamous cell carcinoma with the exception of three
adeno-squamous carcinomas of the uterine cervix. None of the
specimens were classified as atypical cells of uncertain significance
(ASCUS). The results were available via the patient’s clinic
records, and the pathologist entered them into the database. The
records were then compiled and securely shared with Duke
University.
HPV genotyping. ThinPrepH specimens and homogenized
biopsy specimens were shipped to the University of Hawaii Cancer
Center. DNA was extracted and amplified by PCR targeting of a
450 bp region within the HPV L1 gene using the PGMY09/
PGMY11 primers [16]. The human b-globin gene was used as an
internal control for sample accuracy. We were able to obtain viral
DNA analysis for all patient specimens. HPV-positive specimens
were genotyped using the HPV Linear ArrayH (Roche Molecular
Systems Inc., Branchburg, NJ, USA).
Ascertainment of HIV-1 infection status. Plasma and
buffy coat were isolated via centrifugation of peripheral blood
specimens collected in EDTA-containing vacutainer tubes from
the patients. Two rapid HIV-1 tests were used to analyze the
plasma samples for HIV-1 status (Capillus HIV-1/HIV-2, Trinity
Biotech PLC, Bray, Country Wicklow, Ireland and Determine
HIV-1/2, Abbott Laboratories, Abbott Park, IL). The standard
clinical practice of Western blot was used for specimens that were
reactive (Genetic Systems HIV-1 Western blot kit; Bio-Rad,
Hercules, CA).
PEG3 methylation analysis. Genomic DNA was prepared
from cells isolated from the cervical scrapes or from biopsy
specimens using PureGene protocol reagents (Qiagen; Valencia,
CA) and treated with sodium bisulfite using the Zymo Easy-96
DNA methylation kit (Zymo Research, Irvine, CA). Bisulfite
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treatment modifies the DNA by converting unmethylated cyto-
sines to uracils, and leaves methylated cytosines unchanged.
Pyrosequencing was performed using a Qiagen Pyromark Q96
MD Pyrosequencer.
The DMR analyzed is located within the PEG3 promoter region
at chromosome 19q13.43. The pyrosequencing assay for PEG3
was used as previously described [12] with the exception that a
63uC annealing temperature was used for the PCR reaction.
Genomic coordinates for the region amplified by PCR are chr19:
57,351,945–57,352,096 (UCSC Genome Browser, GRCh37/
hg19). The performance of the assay was assessed using defined
mixtures of unmethylated and methylated bisulfite modified
genomic DNA (i.e., 0%, 25%, 50%, 75% 100% methylated;
Epitect Bisulfite Controls; Qiagen).
Statistical Analyses
The mean DNA methylation fractions at the individual CGs
were analyzed and compared among controls, women without
CIN1/2/3 or ICC (n = 147) and the three case groups (CIN1
[n = 21], CIN2/3 [n = 17], and ICC [n = 48]) using F-tests.
Principal components analyses (PCA) were applied to determine
if a single mean represents the methylation fraction at the CG
dinucleotides within the DMR region. Methylation of the CGs was
sufficiently correlated thus allowing a single mean to be used. F-
tests were used to determine if DNA methylation at individual
CGs within PEG3 DMR differed significantly by infection with
high risk (HR) versus low risk (LR) HPV and other HPV
genotypes. Classification of high risk and low risk genotypes was
based on FDA-approved HPV molecular tests (CDC). HR HPV
genotypes included HPV 16,18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59,59 and LR HPV included HPV 6, 11, 26, 66, 68, 70, 73 and,
82 as described previously [15]. Women who tested positive for at
least one HPV genotype based on oncogenic risk were categorized
as HR-HPV, LR-HPV or other HPV.
To estimate odds ratios (OR) and corresponding 95%
confidence intervals (CIs) for the association between CIN/ICC
and changes in DMR methylation, we used multi-polynomial
logistic regression models. All models included methylation using
5% increments with adjustments made for HPV-infection,
pregnancy history, HIV-1 status, and hormonal contraceptive
use. Aberrant methylation was defined as ,25th or .75th
quartiles, since both hypermethylation and hypomethylation of
this locus can lead to deregulation of PEG3 expression and lead to
loss of imprinting [11] [12] [17]. We used chi-square analysis to
test for potential confounders with CIN and cancer status. All
statistical analyses were conducted in SAS 9.1 (SAS Institute,
Cary, NC).
Table 1. Distribution of participant characteristics by case-control status.
Characteristics Control CIN1 CIN2/3 ICC*
N = 147 N = 21 N = 17 N = 48
Mean Age (s.d.) 40.3 (9.9) 35.7 (12.2) 44.7 (9.8) 55.2(12.3)
Ever Pregnant N (%) N (%) N (%) N (%)
Yes 135 (94.8) 18 (85.7) 17 (100) 48 (100)
No 12 (9.2) 3 (14.3) 0 (0) 0 (0)
Oral Contraceptives N (%) N (%) N (%) N (%)
Yes 98 (66.6) 16 (76.2) 10 (58.8) 19 (39.6)
No 47 (31.9) 5 (23.8) 7 (41.2) 29 (60.4)
Missing 2 (1.5) 0 (0) 0 (0) 0 (0)
Any HPV N (%) N (%) N (%) N (%)
$1 HPV 20 (13.6) 12 (57.1) 14 (82.4) 33 (68.8)
No HPV 122 (83) 6 (28.5) 2 (11.8) 4 (8.3)
Missing 5 (3.4) 3 (14.3) 1 (5.8) 11 (22.9)
HPV type Prevalence Single/Multiple Single/Multiple Single/Multiple Single/Multiple
High Risk 4/23 4/18 3/19 8/68
Low Risk/Other 4/19 0/15 1/33 0/25
*ICC/Cancer subtype: 45 patients had squamous cell carcinoma; 3 had adenosquamous carcinomas.
High Risk HPV- 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
Low/Other Risk HPV – 6,11, 26, 40, 42, 55, 61, 62, 69, 70, 72, 73, 81, 82, 83, 84.
doi:10.1371/journal.pone.0056325.t001
Figure 1. Validation of the PEG3 pyrosequencing assay. Defined
mixtures (x-axis) of methylated and unmethylated DNAs were prepared
and analyzed in quintuplicate by pyrosequencing (y-axis). The results
shown represent the mean; error bars indicate standard deviations. The
Pearson rho is 0.953 with a p-value of 0.004.
doi:10.1371/journal.pone.0056325.g001
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Results
Study Population Characteristics
Case groups and controls differed significantly by age, HPV
infection and gravidity (Table 1). The mean age among controls
was 40.3 years (SD = 9.9). Among case groups the average age
increased with severity of lesion (35.7 years, SD = 12.2 for CIN1;
44.7 years, SD = 9.8 for CIN2/3 and 55.2 years, SD = 12.3 for
ICC; p,0.001). The prevalence of HPV infection also increased
with increasing severity of lesion, as 67% of CIN1, 88% CIN2/3
and 89% of ICC had detectable HPV infection (p-value,0.0001).
Gravidity was high, with 94% of controls and 86% of women with
CIN1 reporting that they had ever been pregnant as compared to
100% of the women with CIN2/3 or ICC. Long term OC use was
similar in CIN1 and controls 76% and 68%, respectively, but was
significantly lower among higher grades of CIN (59%) and ICC
(40%).
PEG3 pyrosequencing assay validation
We first validated the performance of the pyrosequencing assay
in quintuplicate using fully methylated and unmethylated DNAs in
defined proportions. At each increase in the amount of methylated
DNA input, there was also an increase in the amount of
methylation measured (Pearson rho = 0. 953; p = 0.004). The
average standard deviation between these replicate measures was
1.59% (range, 0.34% to 3.47%). These results indicate that this
assay has the ability to reproducibly detect differences in
methylation values (Figure 1).
Association between HPV infection status and DNA
methylation at PEG3 DMRs
We examined methylation fractions of 10 CpG sites within the
PEG3 DMR in relation to HPV genotype. As shown in Table 2,
among women infected with at least one HR-HPV genotype, we
found a moderate correlation between methylation of all 10 CpG
sites within the PEG3 DMR and HPV infection (r = 0.34, p-value
,0.0001; range = 0.32 to 0.41). LR-HPV genotypes had a sizably
weaker correlation with PEG3 methylation (r = 0.061, p val-
ue = 0.552). Infection with other HPV genotypes was not
correlated with methylation fractions within the PEG3 DMR
(mean correlation coefficient = 0.0163 p = 0.876).
Table 2. Correlation between High and Low Risk HPV status and methylation fraction means at differentially methylated region
(DMRs) of PEG3.
Chromosomal region and CpG site High Risk HPV Low Risk HPV Other HPV
PEG3 (N = 149) Correlation coefficient (p-value) Correlation coefficient (p-value) Correlation coefficient (p-value)
CpG1 0.40 (,0.0001) 20.01 (0.90) 0.00 (0.98)
CpG2 0.35 (,0.0001) 0.02 (0.86) 0.00 (0.98)
CpG3 0.37 (,0.0001) 0.03 (0.74) 0.13 (0.23)
CpG4 0.32 (,0.0001) 20.01 (0.94) 0.01 (0.93)
CpG5 0.41 (,0.0001) 20.04 (0.67) 0.03 (0.77)
CpG6 0.33 (,0.0001) 20.04 (0.68) 0.02 (0.85)
CpG7 0.36 (,0.0001) 20.01 (0.89) 0.003 (0.98)
CpG8 0.33 (,0.0001) 0.001 (0.99) 0.05 (0.65)
CpG9 0.36 (,0.0001) 20.04 (0.72) 0.02 (0.85)
CpG10 0.37 (,0.0001) 20.01 (0.92) 20.01 (0.94)
Mean 0.34 (,0.0001) 0.06 (0.55) 0.02 (0.87)
High Risk HPV - 16,18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
Low/Other Risk HPV – 6, 11, 26,40, 42, 55, 61, 62, 69, 70, 72, 73, 81, 82, 83, 84.
doi:10.1371/journal.pone.0056325.t002
Table 3. Adjusted odds ratios for the associations between mean DMR methylation for PEG3, HPV status and CIN and ICC.
PEG3 mean (s.d.) *OR, (95% CI), p-value
Control 39.0 (2.8) Ref
CIN 39.2 (5.0) 1.0 (0.79–1.33) p = 0.8
ICC 45.5 (5.8) 1.6 (1.2–2.1) p = 0.0003
HPV (None/Any) OR, (95% CI)
Control 122/20 Ref
CIN 8/26 15.7 (5.1–48.6)
ICC 4/33 29.5 (6.3–38.4)
*Controlling for HIV-1 status, HPV positive status, age, and oral contraceptive (OC) use.
Per 5% methylation increase.
doi:10.1371/journal.pone.0056325.t003
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PEG3 DMR methylation, CIN and ICC
Table 3 summarizes the odds ratios (ORs) and 95% CI for the
association between PEG3 DMR methylation and CIN and ICC
status, adjusted for age, hormonal contraceptive use and any HIV-
1 infection. We found little or no association between mean PEG3
methylation status and CIN1/2/3, (OR = 1.03; 95% CI (0.79–
1.33); p-value = 0.80). However, a 5% increase in methylation
levels at the PEG3 DMR was associated with a nearly two-fold
increase in the risk of ICC (OR = 1.6; 95% CI 1.2–2.1; p-
value = 0.0003). As expected, infection with any HPV genotype
was also associated with a higher risk of CIN1-3 (OR = 15.7 95%
CI(5.1–48.6)) and ICC (OR = 29.5, 95% CI (6.3–38.4)).
Discussion
Our key findings in this case-control study of Tanzanian women
are that after adjusting for HPV infection, age, OC use, and HIV-
1 status, a 5% increase in DNA methylation at the PEG3 DMR
was associated with a 1.6 fold increase in ICC risk. We also found
that PEG3 DMR hypermethylation was correlated with HPV
infection; a correlation that was stronger for high risk as compared
to low risk HPV infection. As would be expected, HPV infection
was associated with increased risk of CIN1/2/3 and ICC. We
present the first evidence in support of the hypothesis that aberrant
methylation of the PEG3 DMR is an important co-factor in the
development of ICC, especially among women infected with HR
HPV.
Our data suggests that increasing grade of lesion from CIN to
ICC correlates with HPV infection and PEG3 DMR hypermethy-
lation and is consistent with DNA methylation-mediated repres-
sion of PEG3 as found in previous studies. Hypermethylation of
various genes (i.e. MGMT, FHIT, GSTP1, and MHL1) in ICC case
control sudies has been reported [18] [19] [20]. Previous studies
have reported DNA methylation changes and HPV status in head
and neck squamous cell cancer [21]. These findings support the
idea that the presence of aberrantly methylated genes could be
used as a relatively sensitive and specific screening assay to detect
CIN and ICC. These previous studies did not investigate PEG3.
To our knowledge this is the first study done with a human
population that investigated the relationship between PEG3 DMR
status and HPV infection and how this plays a role in CIN and
ICC. Although cause and effect cannot be established in this case-
control study, our findings suggest that PEG3 DMR methylation is
a potential mechanism by which susceptibility to progression to
ICC may occur, and thus may be a useful marker to identify CIN
cases likely to progress.
The mechanisms by which PEG3 DNA methylation increases
risk of ICC are unclear. However, there is evidence suggesting that
PEG3 plays an important biological role in p53/c-myc mediated
apoptosis, implicating PEG3 as a gene whose function may be in
part to prevent carcinogenesis [8] [9]. The p53-mediated
apoptosis pathway has two potential outcomes: induction of a)
growth arrest or b) cell death; Peg3 has been shown to play a role
downstream of p53 activating apoptosis via its interaction with
Bax. Peg3 interacts with Bax, resulting in apoptosis [8]. These
prior reports, together with our findings, support the hypothesis
that PEG3 functions as an important tumor suppressor in
carcinogenesis.
The association found here is consistent with findings from in
vitro and in vivo studies showing that the PEG3 promoter is
hypermethylated with consequent transcriptional repression in
ovarian and endometrial cancers [12] [11]. In cervix, ovarian, and
endometrial cancer cell lines PEG3 is silenced suggesting that
during carcinogenesis, hypermethylation may be selected for in
order to inhibit the pro-apoptotic function of PEG3. Our case
control study shows an association between hypermethylation of
PEG3 and ICC but not CIN, suggesting that these methylation
alterations take place during transformation rather than in pre-
cancerous lesions. Alternatively, the attenuation in risk may be due
to combining low grade CIN largely comprised of lesions likely to
regress, with higher-grade CIN cases, the majority of which have
potential to progress and become ICC. Intriguingly, the correla-
tion of HPV infection, an etiologic agent of ICC, and PEG3
hypermethylation is consistent with a multi-step process that starts
with epigenetic mechanisms and HPV infection.
The main limitation of this study is the small sample size to
examine PEG3 DMR methylation in relation to grade specific
CIN, after accounting for the effect of HPV infection. It is possible
that our inability to find associations between PEG3 methylation
and CIN was due to combining CIN (in whom the majority or
women are likely to regress) and CIN2 and CIN3 (in whom a
smaller proportion persist or progress) [22]. However, we had
adequate statistical power to evaluate PEG3 and ICC risk. Another
limitation is the case-control design, limiting our ability to infer
PEG3 methylation as an important factor in progression. However,
identifying methylation marks associated with case-control differ-
ences is a necessary step allowing for examination of this marker in
longitudinal studies currently under way by several groups [23].
Despite these limitations, we found hypermethylation of the
PEG3 DMR increased the risk for ICC after adjusting for known
confounders. We also found a strong correlation between HPV
genotype and DNA methylation at the PEG3 DMR. Cytosine
methylation is a stable modification in human tissue samples, and
therefore PEG3 DMR methylation status could potentially be used
as a marker to identify CIN likely to progress to ICC. Larger
studies in a more diverse study population are required to replicate
these findings.
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